TAT and non-Hodgkin lymphoma: The first clinical study that applied the lentiviral vector for anti-HIV gene delivery introduced a triple combination of a Tat/Rev shRNA, a TAR decoy, and a CCR5 ribozyme into CD34+ cells of patients with AIDS-related non-Hodgkin lymphoma (NHL).